Connectivity firm Merge Technologies reported 55% revenue growth in its first quarter as a public company. The Milwaukee-based software developer credited new product sales and an expanded sales force for the strong performance.For the period
Connectivity firm Merge Technologies reported 55% revenue growth in its first quarter as a public company. The Milwaukee-based software developer credited new product sales and an expanded sales force for the strong performance.
For the period (end-March), Merge posted revenues of $2.6 million, compared with $1.7 million in 1997. The company had a net loss of $56,000, compared with a net loss of $45,000 in the same period last year.
In quarterly highlights, Merge shipped two beta units of its CD-based MergeARK archiving offering. The firm also has been granted a patent for CaseWorks, the first product in Merges line of Networked Image Management offerings, which the company believes will facilitate the development of electronic patient records. CaseWorks is a radiology work-flow management tool that uses a MergeReader hand-held unit to mark films that should be included in a patients EPR. Merge expects CaseWorks to begin shipping in mid-1998.
Since Merges debut on the NASDAQ SmallCap Market in January, the companys stock has seen its share price climb to a high of $7, before falling below its initial public offering price of $6. As of May 4, Merge shares closed at $5.03, down 16.2% from the IPO price.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.